The Novartis community would like to express our thoughts and condolences to all of those affected by the bushfires in Australia.
Up to 8,800 hospital admissions and hundreds of deathscould be prevented, according to first Seasonal Vulnerability Report1
Thousands of older Australians are being hospitalised as temperatures plummet across Australia, with a new report revealing a 32 per cent spike in admissions during winter compared to summer for deadly and common heart conditions.1
Novartis today announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis. The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
This site is intended for an audience in Australia